Clinical trials: Late Effect
Stroke Sequelae, Cognitive Impairment
Remote Bimanual Virtual Rehabilitation Post CVD
The aim of the study is to develop the BrightBrainer G (grasp), a game-based upper-extremity motor and cognitive rehabilitation system using custom virtual reality simulations.
- Conditions
- Stroke Sequelae, Cognitive Impairment, Depression
- Trial name
- NCT04713384
- Testing
- Integrative tele-rehalitation of chronic stroke survivors using custom therapeutic games
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Grigore Burdea
COVID-19 Pneumonia, COVID-19 Respiratory Infection
Phase 2/Phase 3 Study To Evaluate The Efficacy And Safety Of Ramatroban Along With The Standard Of Care In Subjects Hospitalized For COVID Pneumonia
Phase II/Phase III study to evaluate the safety and efficacy of Ramatroban 75 mg tablet against Placebo in subjects hospitalized for pneumonia due to SARS-CoV-2 infection.
- Trial name
- NCT05706454
- Testing
- Ramatroban
- Where
- 7 sites in India
- Volunteers
- 324 people
- Sponsor
- KARE Biosciences
Asthma
The Effect Of AVANDIA On The Late Asthmatic Response
This study is to investigate the effects of AVANDIA on the asthmatic response.
- Trial name
- NCT00318630
- Testing
- Rosiglitazone
- Where
- New Zealand
- Volunteers
- 26 people
- Sponsor
- GlaxoSmithKline
Cardiomyopathy, Hypertrophic, Cardiomyopathy, Hypertrophic, Familial
Open-Label Study of Perhexiline in Patients With Hypertrophic Cardiomyopathy and Moderate to Severe Heart Failure
The purpose of this study is to evaluate the effect of perhexiline on exercise performance (efficacy) and safety in patients with hypertrophic cardiomyopathy and moderate-to-severe heart failure following dosing for 16 weeks.
- Trial name
- NCT02862600
- Testing
- Perhexiline, Use of bioanalytical assay to monitor plasma levels of perhexiline
- Where
- 11 sites in United States
- Volunteers
- 35 people
- Sponsor
- Heart Metabolics Limited
Ventricular Septal Defect, Atrioventricular Septal Defect
A Study Evaluating the Efficacy and Safety of IV L-Citrulline for the Prevention of Clinical Sequelae of Acute Lung Injury Induced by Cardiopulmonary Bypass in Pediatric Patients Undergoing Surgery for Congenital Heart Defects
This is a randomized, double-blind, placebo controlled, multicenter study to compare the efficacy and safety of L-citrulline versus placebo in patients undergoing surgery for congenital heart defects.
- Conditions
- Ventricular Septal Defect, Atrioventricular Septal Defect, Primum Atrial Septal Defect
- Trial name
- NCT05253209
- Testing
- L-citrulline, Plasmalyte A
- Where
- 10 sites in United States
- Volunteers
- 64 people
- Sponsor
- Asklepion Pharmaceuticals, LLC
Acute Respiratory Distress Syndrome
R-3750 in Patients With Late-Stage Acute Respiratory Distress Syndrome (ARDS)
The goal of this clinical trial is to learn if R-3750 is safe in [in patients with late-stage, non-resolving Acute Respiratory Distress Syndrome (ARDS) . The main question[s] it aims to answer are: 1.
- Trial name
- R-3750 ARDS (NCT07646028)
- Testing
- R-3750
- Volunteers
- 20 people
- Sponsor
- Rise Therapeutics LLC
Sequelae of Viral Hepatitis, Transplantation Infection
Randomized Phase II Study of Hepatitis C Immune Globulin Intravenous (Human), Civacir(TM), in Liver Transplantation
A Phase 2 study to evaluate safety, pharmacokinetics and efficacy of Hepatitis C Immune Globulin Intravenous (human) [Civacir(TM)] for preventing or reducing the impact of recurrent HCV infection following liver transplantation.
- Conditions
- Sequelae of Viral Hepatitis, Transplantation Infection, Evidence of Liver Transplantation
- Trial name
- NCT00473824
- Testing
- Hepatitis C Immune Globulin Intravenous (Human) 5%
- Where
- 3 sites in United States
- Volunteers
- 7 people
- Sponsor
- ADMA Biologics, Inc.
Parkinson Disease
Continued Efficacy and Safety of Apomorphine in Patients With Late-Stage Parkinsons Disease
Study to measure the continued effectiveness of apomorphine after previous exposure of at least three months duration.
- Trial name
- NCT00200525
- Testing
- apomorphine HCl injection
- Volunteers
- 60 people
- Sponsor
- Mylan Bertek Pharmaceuticals
Asthma
Randomised Study Comparing the Effects of Inhaled FF/GW642444M Combination, FF and GW642444M on an Allergen Induced Asthmatic Response
We propose to use an inhaled allergen challenge model to explore the individual contributions of the components of a novel long-acting beta agonist/ inhaled corticosteroid combination product and its components on protection from…
- Trial name
- NCT01128595
- Testing
- FF/GW642444M, GW642444M, Fluticasone Furoate
- Where
- 4 sites in Australia, New Zealand and 1 more
- Volunteers
- 27 people
- Sponsor
- GlaxoSmithKline
Parkinson Disease
Continued Efficacy of Apomorphine After Previous Exposure of at Least Three Months
The objective of this study was to measure the continued efficacy of apomorphine after previous exposure of at least three months duration.
- Trial name
- NCT00200512
- Testing
- apomorphine HCl injection
- Where
- 2 sites in United Kingdom
- Volunteers
- 16 people
- Sponsor
- Mylan Bertek Pharmaceuticals
Endovascular Thrombectomy, Ischemic Cerebrovascular Accident
A Trial to Assess the Efficacy and Safety of OTR4132-MD in Patients With Acute Ischemic Stroke
The MaTRISS 2 study is a phase 2 randomized, double-blinded and placebo-controlled trial aimed at recruiting 60 subjects (30 placebo and 30 active) from 15 stroke centers in France.
- Trial name
- MATRISS-II (NCT06700824)
- Testing
- OTR4132
- Where
- 15 sites in France
- Volunteers
- 60 people
- Sponsor
- Organ, Tissue, Regeneration, Repair and Replacement
COVID-19, SAR
(CBDRA60) to Prevent or Reduce Symptoms of COVID-19 and Prevention of Post-Acute Sequelae of SARS-CoV-2 Infection PASC
Coronavirus disease (COVID-19), caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), presents a major threat to human health.
- Trial name
- NCT04777981
- Testing
- CBDRA60 supplement
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Anewsha Therapeutics Inc.
Alzheimers Disease
Clinical Utility of Early vs. Late Blood Biomarker Testing for Alzheimer's Disease
The goal of this study is to evaluate whether use of the PrecivityAD2 blood biomarker assay with early result disclosure along with discretionary Precivity-ApoE proteotype testing will shorten the time to Alzheimer's Disease or…
- Trial name
- ADELAIDE (NCT06856681)
- Testing
- PrecivityAD2 - Early Testing, PrecivityAD2 - Delayed Testing
- Sponsor
- C2N Diagnostics
Long Covid
Long COVID Ultrasound Trial
The research objective is to assess the safety and potential efficacy of spleen ultrasound stimulation as an intervention for Long COVID in a pilot study.
- Trial name
- LOCUS (NCT06189066)
- Testing
- Splenic Ultrasound
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- SecondWave Systems Inc.
Spasticity as Sequela of Stroke
A Study to Estimate How Often Post-stroke Spasticity Occurs and to Provide a Standard Guideline on the Best Way to Monitor Its Development
This study will monitor patients during the first year following their stroke. Stroke is a very serious condition where there is a sudden interruption of blood flow in the brain.
- Trial name
- EPITOME (NCT06055725)
- Where
- 55 sites in United States, France and 5 more
- Volunteers
- 1,057 people
- Sponsor
- Ipsen
Allergic Asthma
A Phase IIa Study of Subcutaneous AER 001 on Antigen Challenge In Atopic Asthmatic Subjects (28 Day Study)
This is a single center, double-blind, randomised parallel group design study to investigate the effects of AER 001 on the late phase asthmatic resonse in asthmatic subjects.
- Trial name
- NCT00535028
- Testing
- AER 001
- Where
- United Kingdom
- Volunteers
- 24 people
- Sponsor
- Aerovance, Inc.
Glycogen Storage Disease Type II (GSD-II), Pompe Disease (Late-onset)
Pompe Pregnancy Sub-Registry
This Sub-registry is a multicenter, international, longitudinal, observational, and voluntary program designed to track pregnancy outcomes for any pregnant woman enrolled in the Pompe Registry, regardless of whether she is…
- Conditions
- Glycogen Storage Disease Type II (GSD-II), Pompe Disease (Late-onset), Glycogenesis 2 Acid Maltase Deficiency
- Trial name
- NCT00567073
- Where
- 35 sites in United States, Australia and 7 more
- Volunteers
- 20 people
- Sponsor
- Genzyme, a Sanofi Company
Cicatrix, Scar Prevention
Evaluation of the Safety, Pharmacokinetics, and Preliminary Effect on Scar Formation by RXI-109
The primary purpose of this study is to evaluate the safety and tolerability of a single intradermal administration of RXI-109 at small surgical incisions in the abdominal skin that will later be removed during an elective…
- Trial name
- NCT01640912
- Testing
- RXI-109
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- RXi Pharmaceuticals, Corp.
Sleep, Alcohol Aftereffects
Cheers Health Restore Study
This observational cohort study, sponsored by Cheers Health and conducted by Principal Investigator Dr. Nirav Shah, aims to evaluate the potential role of Cheers Restore in supporting sleep quality, physiological recovery, and…
- Conditions
- Sleep, Alcohol Aftereffects, Recovery
- Trial name
- NCT07069608
- Testing
- Cheers Restore
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Cheers Health
Alcohol Aftereffects, Anxiety
A Clinical Study to Assess the Effects of JoyRise Recovery Powder on Mitigating Alcohol Aftereffects.
This study assesses the effectiveness of JoyRise Recovery Powder in reducing alcohol aftereffects, cognitive impairment, and anxiousness among participants aged 35-54 who consume alcohol.
- Conditions
- Alcohol Aftereffects, Anxiety, Cognitive Impairment
- Trial name
- NCT06575972
- Testing
- JoyRise Recovery Powder
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Joyrise